secwatch.observer — SEC 8-K summary
======================================

Issuer:     Biohaven Ltd. (BHVN)
CIK:        0001935979
Form:       8-K
Filed at:   2025-05-12T23:59:59+00:00
Accession:  0001935979-25-000053
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Biohaven Q1 net loss $221.7M; announces $600M Oberland capital deal for troriluzole launch
--------------------------------------------------------------------------------

- Net loss of $221.7M ($2.17 per share); non-GAAP adjusted net loss $166.8M ($1.64 per share).
- Cash as of April 30, 2025: ~$518M, after receiving $250M first tranche from Oberland Capital.
- $600M non-dilutive note purchase with Oberland; includes regulatory milestone and royalty on troriluzole sales.
- Troriluzole NDA for SCA under FDA priority review; PDUFA in Q3 2025; mid-cycle review completed without advisory committee.
- Upcoming milestones: pivotal topline data for troriluzole in OCD in 1H 2025, BHV-7000 MDD data in 2H 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1935979/000193597925000053/0001935979-25-000053-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1935979/000193597925000053/bhvn-20250512.htm
  HTML page:      https://secwatch.observer/filing/0001935979-25-000053

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer